Pfizer Projects 2025 Revenue of $61B-$64B, Adjusted EPS of $2.80-$3.00, Stock Rises 3%

Dec 17, 2024, 12:06 PM

Pfizer Inc. ($PFE) has provided its full-year guidance for 2025, projecting revenues between $61 billion and $64 billion, which aligns closely with Wall Street expectations of $63.23 billion. The company also anticipates adjusted diluted earnings per share (EPS) in the range of $2.80 to $3.00, slightly below the expected $2.90. Pfizer's guidance reflects an operational growth of 10% to 18% from the midpoint of its 2024 estimates. Additionally, the company plans to implement a manufacturing optimization program aimed at achieving $500 million in cost savings in 2025, building on an earlier $4 billion cost realignment strategy. The stock rose more than 3% in pre-market trading following the announcement, as the company seeks to address criticism regarding its turnaround strategy from activist hedge fund Starboard Value. Pfizer's gross leverage position is targeted at 3.25x, down from approximately 3.5x in the last quarter.